Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters

New 23,700- square-foot facility houses the Company’s Houston-based employees and supports remote corporate employees

Ribbon-cutting ceremony to be held May 25

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced it will host a ribbon cutting ceremony and reception for national, state and local officials, employees and other members of the community, at its new corporate headquarters on May 25, 2021, from 3:00 p.m. – 6:00 p.m. Central time. The Company’s new headquarters is located at 505 South Friendswood Drive in Friendswood, Texas.

“At Castle, we are committed to improving the lives of patients with skin cancer and other dermatologic diseases,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The Company was founded in 2007 in Friendswood, Texas. We are excited to move into our new headquarters, which we expect to facilitate the continued growth of our business and help us remain focused on our commitment to patients.

“Company-wide, we grew the size of our team in 2020 by almost 50% and as planned, have continued to add employees in 2021 to date, with expectations to add even more team members throughout 2021. The company’s vision is to provide a comprehensive offering of prognostic and diagnostic tests in skin cancer and dermatologic diseases with high unmet clinical need to guide diagnosis and patient management. This month, we celebrate our progress toward this vision, while remaining a proud member of the Friendswood community.”

Castle has laboratory operations in Phoenix, and in 2020, the Company doubled the footprint of its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA)-certified primary laboratory facility. The Company expanded the space to approximately 23,500 square feet by adding a new laboratory facility in close proximity to the primary facility to support growth and provide certain operational redundancy. Earlier in 2021, the Company further expanded this facility to include approximately 3,600 additional square feet.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com. Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.

For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning the ability of the Company’s new headquarters to facilitate growth of the Company’s business and help the Company remain focused on its commitment to patients and the Company’s expectations regarding the growth in the size of its team. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business and the risks set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005104/en/

Investor and Media Contact:
Camilla Zuckero
832-835-5158
[email protected]

Source: Castle Biosciences, Inc.

You May Also Be Interested In

• Exicure Inc. (XCUR) Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
• Golub Capital BDC (GBDC) Announces Preliminary Fiscal Year 2024 Second Quarter Financial Results and Declares Fiscal Year 2024 Third Quarter Distribution
• True Search and Leadership Circle Partner to Deliver Innovative Succession and Talent Assessment and Search Solutions